Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ) has provided an announcement.
Fuso Pharmaceutical Industries has signed a ¥13.4 billion syndicated commitment-type term loan arranged by Sumitomo Mitsui Banking Corporation to finance its key manufacturing expansion plan. The funds will support construction of a second formulation building at the Okayama Factory, creation of a new powder dialysate line, and consolidation of functions from the Daito Factory to strengthen its supply system.
This investment under the FUSO VISION 2030 Next Stage plan is positioned as a core measure to lift the company’s domestic dialysis supplies market share from about 50% toward a 55% target by fiscal 2030. The loan, backed by a consortium of major Japanese banks and running through early 2029, is expected to have only an immaterial impact on results for the year ending March 31, 2026, but should bolster long-term growth and corporate value.
The most recent analyst rating on (JP:4538) stock is a Hold with a Yen2448.00 price target. To see the full list of analyst forecasts on Fuso Pharmaceutical Industries,Ltd. stock, see the JP:4538 Stock Forecast page.
More about Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. is a Japanese drug maker focused on dialysis-related pharmaceuticals and supplies, where it holds around 50% of the domestic market share by patient numbers. The company operates multiple production sites, including its Okayama and Daito factories, and aims to further expand its presence in the dialysis market as part of its medium-term growth strategy.
Average Trading Volume: 30,803
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen21.26B
Find detailed analytics on 4538 stock on TipRanks’ Stock Analysis page.